GlassScriptPhysician profile
Jenna Wagenblatt
NPI 1578286936
$2,779.27
in general payments reported to CMS, 2019-2025
27 companies · $989 in 2025
The $989 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $427 · 2024: $1,363 · 2025: $989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,779.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $309.67 | 2023-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Abbvie INC. | $293.06 | 2023-2025 | |
| Lilly USA, LLC | $277.84 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $157.76 | 2023-2024 | Spravato |
| Novo Nordisk INC | $154.62 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $151.35 | 2025 | Caplyta |
| Madrigal Pharmaceuticals | $139.69 | 2025 | Rezdiffra |
| Astellas Pharma US INC | $135.68 | 2024-2025 | Veozah |
| Kyowa Kirin, INC. | $127.24 | 2024-2025 | Crysvita |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.03 | 2023-2025 | Xifaxan, Trulance |
| Pfizer INC. | $98.70 | 2024-2025 | |
| Exact Sciences Corporation | $97.09 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $87.06 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $84.20 | 2023-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amgen INC. | $79.60 | 2023-2024 | Repatha, Otezla, Evenity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $76.56 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Insulet Corporation | $75.28 | 2024-2025 | Omnipod |
| Corcept Therapeutics | $70.78 | 2025 | Korlym |
| Edwards Lifesciences Corporation | $69.13 | 2024-2025 | Sapien 3 Ultra Resilia |
| Phathom Pharmaceuticals, INC. | $38.42 | 2024 | Voquezna |
| Tactile Systems Technology INC | $33.00 | 2025 | Flexitouch Plus, Nimbl |
| Takeda Pharmaceuticals U.S.A., INC. | $27.38 | 2023 | Trintellix |
| Alk-Abello, INC | $24.81 | 2024 | Ragwitek, Odactra, Grastek |
| Gilead Sciences, INC. | $20.38 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $20.06 | 2024 | Rexulti |
| Lundbeck LLC | $14.56 | 2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $14.32 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Wagenblatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.